EyeGate Pharmaceuticals

Major Drugs - Waltham, MA, US

EyeGate Pharmaceuticals Details

Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye.Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid ("HA"), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel ("OBG"), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy ("PRK") surgery.Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients.

EyeGate Pharmaceuticals logo, EyeGate Pharmaceuticals contact details
Employees: 20 - 49
HQ: 781-788-8869
Location: Waltham, MA, US
Revenue: 2.5 - 5 Million
Pharmaceutical research and development eye disease eye disorders ophthalmology ophthalmic drugs anterior uveitis cataract surgery Clinical trials ocular disease corneal disease superficial punctate kertopathy B2B Major Drugs Pharmaceutical Preparations Pharmaceuticals
EyeGate Pharmaceuticals Technologies
Email Providers

Outlook

Load Balancers

Nginx

CMS

WP Engine

Other

Mobile Friendly

Hosting

Google Cloud Hosting

View All Technologies Used At EyeGate Pharmaceuticals

Contacting EyeGate Pharmaceuticals: Connect with Executives and Employees

Get in Touch with EyeGate Pharmaceuticals Executives and Employees

Connecting with EyeGate Pharmaceuticals's Executives and Workforce

Accessing Contact Information for EyeGate Pharmaceuticals Executives

Connecting with EyeGate Pharmaceuticals: Reach Out to Their Team

Discover How to Contact EyeGate Pharmaceuticals Executives and Staff

Looking to connect with EyeGate Pharmaceuticals executives or employees?

Seeking to Get in Touch with EyeGate Pharmaceuticals Executives or Staff?

Want to Reach Out to EyeGate Pharmaceuticals Executives or Team Members?

In Search of Contact Details for EyeGate Pharmaceuticals Professionals?

Connecting with EyeGate Pharmaceuticals: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z